Modulation of angiogenesis by thyroid hormone and hormone analogues: Implications for cancer management

Angiogenesis

Volumn 17, Issue 3, 2014, Pages 463-469

  Mousa, Shaker A ^a   Lin, Hung Yun ^b   Tang, Heng Yuan ^a   Hercbergs, Aleck ^c   Luidens, Mary K ^d   Davis, Paul J ^a,d  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c LERNER RESEARCH INSTITUTE   (United States)

^d ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Angiogenesis inhibition; Cancer chemotherapy; Integrin v 3; Thyroid hormone

Indexed keywords

ANGIOTENSIN II; BRADYKININ; CHEMOKINE RECEPTOR CX3CR1; CX3C CHEMOKINE; CXCL2 CHEMOKINE; CXCL3 CHEMOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; FRACTALKINE; LIPOPOLYSACCHARIDE; PLATELET DERIVED GROWTH FACTOR; THROMBOSPONDIN 1; THYROID HORMONE; THYROID HORMONE DERIVATIVE; VASCULOTROPIN; VITRONECTIN RECEPTOR; ANGIOGENIC FACTOR; CYTOKINE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; CANCER CHEMOTHERAPY; CELL MOTILITY; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; CX3CL1 GENE; CX3CR1 GENE; DISEASE ASSOCIATION; EGFR GENE; FGF2 GENE; GENE EXPRESSION REGULATION; HORMONE ACTION; HUMAN; MICROVASCULARIZATION; MOLECULAR INTERACTION; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; TSP1 GENE; TUMOR CELL; TUMOR MICROENVIRONMENT; ANIMAL; CELL MOTION; CHEMISTRY; DRUG EFFECTS; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; VASCULARIZATION;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CELL MOVEMENT; CYTOKINES; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THYROID HORMONES;

EID: 84903886307     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-014-9418-5     Document Type: Review

References (55)

1. Folkman J (2006) Angiogenesis. Annu Rev Med 57:1-18
2. Ebos JM, Kerbel RS (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 8:210-221
3. Eklund L, Bry M, Alitalo K (2013) Mouse models for studying angiogenesis and lymphangiogenesis in cancer. Mol Oncol 7:259-282
4. Sun QM, Miao ZH, Lin LP, Gui M, Zhu CH, Xie H, Duan WH, Ding J (2009) BB, a new EGFR inhibitor, exhibits prominent anti-angiogenesis and antitumor activities. Cancer Biol Ther 8:1640-1647
5. Bertrand-Duchesne MP, Grenier D, Gagnon G (2010) Epidermal growth factor released from platelet-rich plasma promotes endothelial cell proliferation in vitro. J Periodontal Res 45:87-93
6. Ozkan EE (2011) Plasma and tissue insulin-like growth factor-1 receptor (IGF-1R) as a prognostic marker for prostate cancer and anti-IGF-1R agents as novel therapeutic strategy for refractory cases: a review. Mol Cell Endocrinol 344:1-24
7. Haleagrahara N, Chakravarthi S, Mathews L (2011) Insulin like growth factor-1 (IGF-1) causes overproduction of IL-8, an angiogenic cytokine, and stimulates neovascularization in isoproterenol-induced myocardial infarction in rats. Int J Mol Sci 12:8562-8574
8. Piecewicz SM, Pandey A, Roy B, Xiang SH, Zetter BR, Sengupta S (2012) Insulin-like growth factors promote vasculogenesis in embryonic stem cells. PLoS One 7(2):e32191
9. Schneller M, Vuori K, Ruoslahti E (1997) Alphavbeta3 integrin associates with activated insulin and PDGFbeta receptors and potentiates the biological activity of PDGF. EMBO J 16:5600-5607
10. Tsou R, Isik FF (2001) Integrin activation is required for VEGF and FGF receptor protein presence on human microvascular endothelial cells. Mol Cell Biochem 224:81-89
11. De S, Razornova O, McCabe NP, O'Toole T, Qin J, Byzova TV (2005) VEGF-integrin interplay controls tumor growth and vascularization. Proc Natl Acad Sci USA 102:7589-7594
12. Montenegro CF, Salla-Pontes CL, Ribeiro JU, Machado AZ, Ramos RF, Figueiredo CC, Morandi V, Selistre-de-Araujo HS (2012) Blocking αvβ3 integrin by a recombinant RGD disintegrin impairs VEGF signaling in endothelial cells. Biochimie 94:1812-1820
13. Plow EF, Haas TA, Zhang L, Loftus J, Smith JW (2000) Ligand binding to integrins. J Biol Chem 275:21785-21788
14. Wei S, Said-Al-Naief N, Hameed O (2009) Estrogen and progesterone receptor expression is not always specific for mammary and gynecologic carcinomas: a tissue microarray and pooled literature review study. Appl Immunohistochem Mol Morphol 17:393-402
15. Shimizu K, Hirami Y, Saisho S, Yukawa T, Maeda A, Yasuda K, Nakata M (2012) Membrane-bound estrogen receptor-α expression and epidermal growth factor receptor mutation are associated with a poor prognosis in lung adenocarcinoma patients. World J Surg Oncol 10:141
16. Davis PJ, Davis FB, Mousa SA, Luidens MK, Lin HY (2011) Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol 51:99-115
17. Fagiani E, Christofori G (2013) Angiopoietins in angiogenesis. Cancer Lett 328:18-26
18. Lawler PR, Lawler J (2012) Molecular basis for the regulation of angiogenesis by thrombospondin-1 and -2. Cold Spring Harb Perspect Med 2(5):a006627
19. Patiar S, Harris AL (2006) Role of hypoxia-inducible factor-1 alpha as a cancer therapy target. Endocr Relat Cancer 13(Suppl 1):S61-S75
20. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R (2009) Hif-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem 9:1084-1101
21. Wilson PM, LaBonte MJ, Lenz HJ (2013) Assessing the in vivo efficacy of biological antiangiogenic therapies. Cancer Chemother Pharmacol 71:1-12
22. Majumder S, Piquet AC, Dufour JF, Chatterjee S (2013) Study of the cellular mechanism of Sunitinib mediated inactivation of activated hepatic stellate cells and its implications in angiogenesis. Eur J Pharmacol 705:86-95
23. Davis FB, Mousa SA, O'Connor L, Mohamed S, Lin HY, Cao HJ, Davis PJ (2004) Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ Res 94:1500-1506
24. Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S, Davis PJ (2005) Integrin alphavbeta 3 contains a cell surface receptor for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146:2864-2871
25. Mousa SA, Bergh JJ, Dier E, Rebbaa A, O'Connor LJ, Yalcin M, Aljada A, Dyskin E, Davis FB, Lin HY, Davis PJ (2008) Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 11:183-190
26. Wong VW, Crawford JD (2013) Vasculogenic cytokines in wound healing. Biomed Res Int 2013:190486
27. Lin HY, Sun M, Tang HY, Lin C, Luidens MK, Mousa SA, Incerpi S, Drusano GL, Davis FB, Davis PJ (2009) l-Thyroxine vs. 3,5,3′-triiodo-l-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 296:C980-C991
28. Incerpi S, Lin HY, De Vito P, Fiore AM, Ahmed RG, Salvia R, Candelotti E, Luly P, Pedersen JZ, Davis FB, Davis PJ (2013) Thyroid hormone inhibition in L6 myoblasts of IGF-1-mediated glucose uptake and proliferation: new roles for integrin αvβ3. Manuscript submitted
29. Shih A, Zhang S, Cao HJ, Tang HY, Davis FB, Davis PJ (2004) Disparate effects of thyroid hormone on actions of epidermal growth factor and transforming growth factor-α are mediated by 3′,5′-cyclic adenosine monophosphate-dependent protein kinase II. Endocrinology 145:1708-1717
30. Glinskii AB, Glinsky GV, Lin HY, Tang HY, Sun M, Davis FB, Luidens MK, Mousa SA, Hercbergs AH, Davis PJ (2009) Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 8:3554-3562
31. Bharali DJ, Yalcin M, Davis PJ, Mousa SA (2013) Tetraiodothyroacetic acid (tetrac) conjugated PLGA nanoparticles: a nanomedicine approach to treat drug-resistant breast cancer. Nanomedicine 8:1943-1954
32. Farwell AP (2013) Nonthyroidal illness syndrome. Thyroid 20:478-484
33. Leonard JL, Farwell AP (1997) Thyroid hormone-regulated actin polymerization in brain. Thyroid 7:147-151
34. Stefansson S, Su EJ, Ishigami S, Cale JM, Gao Y, Gorlatova N, Lawrence DA (2007) The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin. J Biol Chem 282:15679-15689
35. Mousa SA, Davis FB, Mohamed S, Davis PJ, Feng X (2006) Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional in vitro microvascular endothelial sprouting model. Int Angiol 25:407-413
36. El-Eter E, Rebbaa H, Alkayali A, Mousa SA (2007) Role of thyroid hormone analogues in angiogenesis and the development of collaterals in the rabbit hind limb ischemia model. J Thromb Thrombolysis 5(Suppl 1):375
37. Owen JL, Mohamadzadeh M (2013) Macrophages and chemokines as mediators of angiogenesis. Front Physiol 4:159
38. Davis PJ, Glinsky GV, Lin HY, Incerpi S, Davis FB, Mousa SA, Tang HY, Hercbergs A, Luidens MK (2013) Molecular mechanisms of actions of formulations of the thyroid hormone analogue, tetrac, on the inflammatory response. Endocr Res 38:112-118
39. Kumar AH, Martin K, Turner EC, Buneker CK, Dorgham K, Deterre P, Caplice NM (2013) Role of CX3CR1 receptor in monocyte/macrophage driven neovascularization. PLoS One 8(2):e57230
40. Mousa SA, Yalcin M, Bharali DJ, Meng R, Tang HY, Lin HY, Davis FB, Davis PJ (2012) Tetraiodothyroacetic acid and its nanoformulation inhibit thyroid hormone stimulation of non-small cell lung cancer cells in vitro and their growth in xenografts. Lung Cancer 76:39-45
41. Yalcin M, Lin HY, Sudha T, Bharali DJ, Meng R, Tang HY, Davis FB, Stain SC, Davis PJ, Mousa SA (2013) Response of human pancreatic cancer cell xenografts to tetraiodothyroacetic acid nanoparticles. Horm Cancer 4:176-185
42. Yalcin M, Bharali DJ, Lansing L, Dyskin E, Mousa SS, Hercbergs A, Davis FB, Davis PJ, Mousa SA (2009) Tetraiodothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res 29:3825-3831
43. Yalcin M, Dyskin E, Lansing L, Bharadi DJ, Mousa SS, Bridoux A, Hercbergs AH, Lin HY, Davis FB, Glinsky GV, Glinskii AB, Ma J, Davis PJ, Mousa SA (2010) Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 95:1972-1980
44. Yalcin M, Bharali DJ, Dyskin E, Dier E, Lansing L, Mousa SS, Davis FB, Davis PJ, Mousa SA (2010) Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid 20:281-286
45. Hercbergs AA, Goyal LK, Suh JH, Lee S, Reddy CA, Cohen BH, Stevens GH, Reddy SK, Peereboom DM, Elson PJ, Gupta MK, Barnett GH (2003) Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II trial. Anticancer Res 23:617-626
46. Aziz SA, Sznol J, Adeniran A, Colberg JW, Camp RL, Kluger HM (2013) Vascularity of primary and metastatic renal cell carcinoma specimens. J Transl Med 11:15
47. Hercbergs AH, Ashur-Fabian O, Garfield D (2011) Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology. Current Opin Endocrinol Diabetes Obes 17:432-436
48. Schmidinger M, Vogl UM, Bojic M, Lamm W, Heinzl H, Haitel A, Clodi M, Kramer G, Zielinski CC (2011) Hypothyroidism in patients with renal cell carcinoma: blessing or curse? Cancer 117:534-544
49. Riesenbeck LM, Bierer S, Hoffmeister J, Kopke T, Papavasilis P, Hertle L, Thielen B, Hermann E (2011) Hypothyroidism correlates with a better prognosis in metastatic renal carcinoma patients treated with sorafenib or sunitinib. World J Urol 29:807-813
50. Okwan-Duodo D, Landry J, Shen XZ, Diaz R (2013) Angiotensin-converting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis. Am J Physiol Regul Integr Comp Physiol 305:R205-R215
51. Stewart JM, Gera L, Chan DC, York EJ, Simkeviciene V, Bunn PA Jr, Taraseviciene-Stewart L (2005) Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists. Peptides 26:1288-1291
52. Song X, Chen Y, Sun Y, Lin B, Qin Y, Hui H, Li Z, You Q, Lu N, Guo Q (2012) Oroxylin A, a classical natural product, shows a novel inhibitory effect on angiogenesis induced by lipopolysaccharide. Pharmacol Rep 64:1189-1199
53. Rakhesh M, Cate M, Vijay R, Shrikant A, Shanjana A (2012) A TLR4-interacting peptide inhibits lipopolysaccharide-stimulated inflammatory responses, migration and invasion of colon cancer SW480 cells. Oncoimmunology 1:1495-1506
54. Melkamu T, Qian X, Upadhyaya P, O'Sullivan MG, Kassie F (2013) Lipopolysaccharide enhances mouse lung tumorigenesis: a model for inflammation-driven cancer. Vet Pathol 50:895-902
55. Mousa SA, Mohamed S, Wexler EJ, Kerr JS (2005) Antiangiogenesis and anticancer efficiency of TA138, a novel alphavbeta3 antagonist. Anticancer Res 25:197-206